Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 12/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17521638 | 0.76 | PCSK9 (0.65) | AGTR1HTR6PCSK9PSEN1PSEN2 | |
| SCHEMBL12496576 | 0.74 | HTR6 (0.43) | AGTR1HTR6MEN1KMT2AMTNR1B | |
| SCHEMBL12496638 | 0.74 | HTR6 (0.44) | AGTR1HTR6MEN1KMT2AMTNR1B | |
| SCHEMBL12093313 | 0.72 | HTR6 (0.70) | HTR6MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL12229940 | 0.72 | NOD2 (0.49) | AGTR1HTR6MEN1KMT2APSEN1 | |
| SCHEMBL6829775 | 0.71 | AKR1C3 (0.48) | AGTR1HTR6MEN1KMT2APSEN1 | |
| Lithium Ion SCHEMBL12496693 | 0.71 | AGTR1 (0.41) | AGTR1HTR6MEN1KMT2AMTNR1B | |
| SCHEMBL2110900 | 0.70 | HTR6 (0.44) | AGTR1HTR6MEN1KMT2ASRC | |
| SCHEMBL597369 | 0.69 | HTR6 (0.46) | AGTR1HTR6PSEN1PSEN2APH1B | |
| SCHEMBL30644289 | 0.69 | HTR6 (0.46) | AGTR1HTR6PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451811-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-8158625-B2 | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2010136491-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | AGTR1 1376/4885HTR6 1924/4885PCSK9 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.